Genomic Testing in Breast Cancer: Clinical Applications and Best Practices - Episode 6
Utilizing the RSClin Tool to Inform Breast Cancer Treatment Decisions in the Practice Setting
Panelists discuss how the RSClin tool provides more personalized information by combining recurrence scores with clinicopathological data, offering patients specific predictions about their prognosis and potential chemotherapy benefit rather than general outcomes for patients with similar scores.
Video Player is loading.
Tools for Result Interpretation
Main Discussion Topics:
- Use of the RSClin tool to individualize risk assessment beyond recurrence score alone
- Integration of clinical-pathological features with genomic information
- Communication approaches with patients about risk and benefit
Key Points for Physicians:
- The RSClin tool combines recurrence score with clinical-pathological data for more precise estimates of recurrence risk and chemotherapy benefit.
- The tool offers multiple visualization options to facilitate patient understanding.
- Physicians should adapt their communication approach based on patient information needs.
Notable Insights:
- Patients often want to know their individual prognosis rather than population-based outcomes.
- Some patients prefer detailed statistical information whereas others simply want clinician recommendations.
Clinical Significance: Tools such as RSClin enhance the clinical utility of genomic testing by providing more individualized risk estimates that can be communicated to patients in ways that match their information preferences.
Related Content:
